PDCD1 and renal cell carcinoma: Nivolumab (Opdivo®) was the first antibody developed against PD-1 and utilized in clinical trials for treatment of melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC)111.